Sol-Gel Technologies (SLGL) Operating Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Operating Margin of 3569.44% for Q1 2026, up 268981.0% year-over-year from N/an in Q1 2025, and up 828.33% quarter-over-quarter from 490.09% in Q4 2025.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Operating Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Operating Margin for 9 consecutive years, with 3569.44% the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Margin rose 268981.0% year-over-year to 3569.44%; the TTM figure through Mar 2026 stood at 29.17% (down 195.0% YoY), while the FY2025 annual figure was 38.88%, up 6525.0% from the prior year.
- Operating Margin rose to 3569.44% in Q1 2026 per SLGL's latest filing, from 490.09% in the prior quarter.
- Across five years, Operating Margin topped out at 3569.44% in Q1 2026 and bottomed at 6205.0% in Q4 2022.
- Historically, Operating Margin has averaged 838.49% across 5 years, with a median of 490.09% in 2025.
- Annual changes were most pronounced in 2022 — Operating Margin sank 627208 bps — and 2023, when it surged 499538 bps.
- Sol-Gel Technologies' Operating Margin stood at 6205.0% in 2022, then soared by 81 bps to 1209.62% in 2023, then sank by 81 bps to 2193.88% in 2024, then jumped by 78 bps to 490.09% in 2025, then soared by 828 bps to 3569.44% in 2026.
- Business Quant data shows SLGL's Operating Margin at 3569.44% in Q1 2026, 490.09% in Q4 2025, and 1572.0% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | -704.23% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -704.23% |
| Mar 31, 2026 | 3,569.44% |
| Dec 31, 2025 | -490.09% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 65.06% |
| Mar 31, 2025 | 879.63% |
| Dec 31, 2024 | -2,193.88% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 29.89% |
| Mar 31, 2024 | 1,440.34% |
| Dec 31, 2023 | -1,209.62% |
| Sep 30, 2023 | -2,961.03% |
| Jun 30, 2023 | -1,098.82% |
| Mar 31, 2023 | 3,687.67% |
| Dec 31, 2022 | -6,205.00% |
| Sep 30, 2022 | -1,388.89% |
| Jun 30, 2022 | 13.16% |
| Mar 31, 2022 | 198,333.33% |
| Dec 31, 2021 | 67.08% |
| Sep 30, 2021 | 95.21% |